Company Overview
Regentis Biomaterials Ltd. operates within the healthcare sector, specifically focusing on the industry of medical instruments and supplies, where it develops and commercializes tissue repair solutions for the United States market. The company's core business revolves around regenerative medicine, utilizing a technology platform that employs a hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen to treat and regenerate damaged or diseased tissues. As of the latest data, the enterprise holds a market capitalization of $16.31M, while specific figures for annual revenue and employee count are not disclosed in the available financial records. This limited market capitalization indicates that Regentis occupies a niche position within the broader healthcare landscape, suggesting a small-cap status that typically characterizes companies with specialized product pipelines rather than mass-market dominance. The absence of disclosed employee count data further reflects the company's current stage of development, where operational scale is likely driven by research and commercialization efforts rather than a large established workforce.
Financial Health
The company reports a net income of $-13,692,000 for the trailing twelve months, while revenue and EBITDA figures are not available in the provided dataset. The significant negative net income relative to the unreported revenue suggests a cost structure where operating expenses heavily outweigh current income, a common characteristic in the early stages of biotechnology and regenerative medicine development. Despite the reported net loss, Regentis maintains a free cash flow of $3.03M, which provides a critical buffer of financial flexibility that allows the company to fund ongoing research and development without immediate reliance on external equity financing. The financial profile presents three distinct margin metrics, all reported as 0.0% for gross margin, operating margin, and profit margin, indicating that the company has not yet generated positive profitability from its sales or operations during the measured period. On the liability side, the company holds $7.38M in cash against $1.20M in debt, resulting in a debt-to-equity ratio of 25.23, which implies a balance sheet structure that is conservative regarding interest-bearing debt despite the leverage ratio appearing high due to a likely low equity base. Liquidity is supported by a current ratio of 2.65, indicating that the company possesses sufficient current assets to cover its short-term obligations with a comfortable margin of safety. Return on equity is not available, but return on assets stands at -107.5%, revealing that the management team is currently utilizing the company's asset base to generate negative returns, a metric typical for growth-stage firms burning through capital to achieve product milestones.
Valuation Assessment
Trailing P/E and forward P/E ratios are both listed as not available due to the company's lack of earnings, which implies that traditional earnings-based valuation models cannot currently be applied to assess the company's expected earnings trajectory. Instead, the market values the company based on its asset base, reflected in a price-to-book ratio of 3.44, which suggests the stock is trading at a significant premium over its book value, potentially reflecting high growth expectations or the strategic value of its intellectual property and technology platform. Alternative valuation metrics such as price-to-sales and EV/EBITDA are also not available, meaning investors must rely on market cap and price-to-book comparisons to gauge relative value. The stock has exhibited notable volatility, trading between a 52-week low of $3.00 and a 52-week high of $8.35, with the current price position needing to be contextualized within this range to understand recent market sentiment. Beta is not available, so the specific sensitivity of the stock price to broader market movements cannot be quantified, though the wide trading range between $3.00 and $8.35 suggests inherent volatility common in small-cap healthcare stocks.
Growth & Income
Revenue growth and earnings growth rates are not available in the current dataset, preventing a direct comparison of whether earnings are growing faster or slower than revenue at this specific point in time. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the company reinvests all available earnings and cash flow back into its operations and research initiatives rather than distributing income to shareholders. This strategy aligns with the typical lifecycle of a regenerative medicine company, where capital retention is prioritized to advance clinical trials and commercialize tissue repair solutions like Gelrin. The overall growth and income profile is defined by a lack of current income generation through dividends or earnings, coupled with an uncertain historical growth rate, placing the company in a phase where value creation depends entirely on future product approvals and market penetration rather than current financial returns or shareholder payouts.